Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/02/08 | 1,181 | 1,181 | 1,130 | 1,150 | -32 | -2.7% | 108,500 |
2021/02/05 | 1,165 | 1,184 | 1,141 | 1,182 | +16 | +1.4% | 93,500 |
2021/02/04 | 1,150 | 1,168 | 1,126 | 1,166 | +22 | +1.9% | 78,300 |
2021/02/03 | 1,140 | 1,160 | 1,112 | 1,144 | +16 | +1.4% | 87,700 |
2021/02/02 | 1,108 | 1,134 | 1,076 | 1,128 | +30 | +2.7% | 88,800 |
2021/02/01 | 1,103 | 1,108 | 1,057 | 1,098 | -21 | -1.9% | 108,600 |
2021/01/29 | 1,163 | 1,177 | 1,104 | 1,119 | -41 | -3.5% | 169,700 |
2021/01/28 | 1,162 | 1,185 | 1,149 | 1,160 | -32 | -2.7% | 90,000 |
2021/01/27 | 1,211 | 1,254 | 1,180 | 1,192 | -19 | -1.6% | 110,500 |
2021/01/26 | 1,242 | 1,253 | 1,206 | 1,211 | -30 | -2.4% | 67,500 |
2021/01/25 | 1,240 | 1,249 | 1,214 | 1,241 | +1 | +0.1% | 72,100 |
2021/01/22 | 1,236 | 1,260 | 1,207 | 1,240 | -7 | -0.6% | 86,000 |
2021/01/21 | 1,245 | 1,250 | 1,202 | 1,247 | -6 | -0.5% | 113,800 |
2021/01/20 | 1,222 | 1,260 | 1,220 | 1,253 | +31 | +2.5% | 89,200 |
2021/01/19 | 1,218 | 1,228 | 1,199 | 1,222 | +2 | +0.2% | 90,900 |
2021/01/18 | 1,202 | 1,282 | 1,200 | 1,220 | -3 | -0.2% | 178,800 |
2021/01/15 | 1,178 | 1,241 | 1,160 | 1,223 | +45 | +3.8% | 164,600 |
2021/01/14 | 1,169 | 1,201 | 1,165 | 1,178 | ±0 | ±0% | 88,300 |
2021/01/13 | 1,202 | 1,227 | 1,165 | 1,178 | -24 | -2% | 113,900 |
2021/01/12 | 1,231 | 1,252 | 1,201 | 1,202 | -56 | -4.5% | 140,500 |
2021/01/08 | 1,229 | 1,272 | 1,199 | 1,258 | +85 | +7.2% | 265,000 |
2021/01/07 | 1,220 | 1,291 | 1,166 | 1,173 | -40 | -3.3% | 126,400 |
2021/01/06 | 1,163 | 1,221 | 1,162 | 1,213 | +45 | +3.9% | 85,000 |
2021/01/05 | 1,174 | 1,186 | 1,148 | 1,168 | -12 | -1% | 62,600 |
2021/01/04 | 1,194 | 1,208 | 1,132 | 1,180 | -15 | -1.3% | 94,300 |
2020/12/30 | 1,182 | 1,214 | 1,178 | 1,195 | ±0 | ±0% | 44,600 |
2020/12/29 | 1,153 | 1,238 | 1,153 | 1,195 | +56 | +4.9% | 96,900 |
2020/12/28 | 1,229 | 1,230 | 1,132 | 1,139 | -46 | -3.9% | 100,100 |
2020/12/25 | 1,210 | 1,253 | 1,185 | 1,185 | -17 | -1.4% | 76,600 |
2020/12/24 | 1,181 | 1,215 | 1,155 | 1,202 | +32 | +2.7% | 73,000 |
2020/12/23 | 1,150 | 1,184 | 1,143 | 1,170 | +48 | +4.3% | 74,900 |
2020/12/22 | 1,183 | 1,183 | 1,120 | 1,122 | -61 | -5.2% | 92,800 |
2020/12/21 | 1,213 | 1,247 | 1,182 | 1,183 | -5 | -0.4% | 78,500 |
2020/12/18 | 1,181 | 1,209 | 1,169 | 1,188 | -11 | -0.9% | 83,200 |
2020/12/17 | 1,192 | 1,251 | 1,190 | 1,199 | +10 | +0.8% | 86,800 |
2020/12/16 | 1,205 | 1,225 | 1,182 | 1,189 | -27 | -2.2% | 95,700 |
2020/12/15 | 1,232 | 1,251 | 1,193 | 1,216 | -46 | -3.6% | 124,500 |
2020/12/14 | 1,224 | 1,262 | 1,200 | 1,262 | -13 | -1% | 197,500 |
2020/12/11 | 1,160 | 1,285 | 1,153 | 1,275 | +102 | +8.7% | 354,000 |
2020/12/10 | 1,244 | 1,265 | 1,155 | 1,173 | -71 | -5.7% | 294,500 |
2020/12/09 | 1,350 | 1,360 | 1,216 | 1,244 | -277 | -18.2% | 653,100 |
2020/12/08 | 1,501 | 1,549 | 1,433 | 1,521 | -32 | -2.1% | 189,000 |
2020/12/07 | 1,657 | 1,661 | 1,538 | 1,553 | -100 | -6% | 143,700 |
2020/12/04 | 1,717 | 1,730 | 1,622 | 1,653 | -64 | -3.7% | 127,000 |
2020/12/03 | 1,738 | 1,795 | 1,711 | 1,717 | -30 | -1.7% | 127,700 |
2020/12/02 | 1,660 | 1,760 | 1,660 | 1,747 | +49 | +2.9% | 158,800 |
2020/12/01 | 1,637 | 1,706 | 1,600 | 1,698 | +39 | +2.4% | 184,200 |
2020/11/30 | 1,720 | 1,760 | 1,650 | 1,659 | -66 | -3.8% | 211,800 |
2020/11/27 | 1,622 | 1,742 | 1,622 | 1,725 | +100 | +6.2% | 152,800 |
2020/11/26 | 1,596 | 1,658 | 1,590 | 1,625 | +29 | +1.8% | 134,700 |
801~
850
件表示中 / 1363件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 58,800円 | - | - | 0.00% | - | 3.93倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
カイノス | 114,800円 | +6.8% | -13.8% | 2.79% | 8.80倍 | 0.77倍 |
|
臨床検査薬の中堅メーカー。生化学、免疫血清学的検査用試薬に重点。共同開発の促進に注力 |
キッズバイオ | 13,000円 | - | - | 0.00% | - | 7.57倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞(SHED)用いた再生医療に力 |
ソレイジア | 2,600円 | +102.6% | - | 0.00% | - | 2.52倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
免疫生物 | 50,300円 | +13.4% | -4.0% | 0.00% | 40.73倍 | 3.70倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
市場注目の銘柄
チャート関連のコラム